Navigation Links
3SBio Inc. Announces Receipt of Amended "Going Private" Proposal at $16.70 Per ADS and Intent to Adjourn Extraordinary General Meeting of Shareholders
Date:4/22/2013

SHENYANG, China, April 22, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the independent committee of its board of directors (the "Independent Committee") has received a proposal letter (the "Proposal Letter") dated April 22, 2013 from Dr. Jing Lou , the Company's Chairman and Chief Executive Officer ("Dr. Lou"), and CPEChina Fund, L.P., an exempted limited partnership registered under the laws of the Cayman Islands and a China-focused private equity fund associated with CITIC Private Equity Funds Management Co. Ltd. ("CITIC PE"), in connection with the proposed merger under the agreement and plan of merger dated as of February 8, 2013, by and among the Company, Decade Sunshine Limited ("Parent") and Decade Sunshine Merger Sub (the "Merger Agreement").

In the Proposal Letter, Dr. Lou and CITIC PE proposed to increase the merger consideration payable to holders of ordinary shares, par value $0.0001 per share, of the Company (the "Shares"), and holders of American Depository Shares of the Company, each representing seven Shares (the "ADSs"), from $2.20 per Share, or $15.40 per ADS, under the Merger Agreement to $2.3857 per Share, or $16.70 per ADS, pursuant to a proposed amendment to the Merger Agreement.  The proposed increase in the merger consideration represents an 8.4% premium to the current merger consideration under the Merger Agreement, a 9.9% premium to the closing price of the ADSs of April 19, 2013, and a 44% premium to the closing price of the ADSs of September 11, 2012, the last trading day prior to the Company's announcement on September 12
'/>"/>

SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. 3SBio Inc. To Present at the DB Access Asia Conference 2012
3. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
4. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
5. 3SBio Inc. Announces Changes to Its Board of Directors
6. Apexigen Announces the Filing of an IND by its Partner, 3SBio
7. 3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
8. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
9. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
10. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
11. 3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... 2010.  Third quarter 2010 net revenues were $42.0 million, ... 2009.  Excluding the recognition of one-time license revenue in ... 44%.  Net loss for the third quarter ended September ...
... 2, 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... cannabis products, is pleased to announce to its shareholders and ... decisions and processes regarding the new class of common shares. ... 1 for 10 new share dividend payment for shareholders of ...
Cached Medicine Technology:ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 9ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results 10Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 2Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010 3
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Oct. 7 All American gymnast, wife and mom-to-be Shannon ... expecting her first baby in late October and has been ... best possible start on life and learning. Now she,s ... moms around the world. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091007/DE88885 ...
... suspect , WEDNESDAY, Oct. 7 (HealthDay News) -- Younger people ... an anterior cruciate ligament repaired, a new study has ... commonly called an ACL. , ACL damage is one of ... data from more than 70,000 people in New York who ...
... those with, without device , WEDNESDAY, Oct. 7 (HealthDay News) ... heart attack does not improve survival, a major European study ... those given the devices, which shock the heart into beating ... as for those who did not get defibrillators in the ...
... Global TV Concepts, manufacturer and creator of the ... World Record title for the ,World,s Largest Cupcake., Weighing ... feet tall and six feet wide, the massive cupcake was ... from slices of the confectionary masterpiece supported breast cancer charities. ...
... Company,s (NYSE: CRDA ; CRDB) European third party ... name of Broadspire, a Crawford company, continuing the leading ... CRDA ; CRDB), the world,s largest independent provider ... the Broadspire brand at the Federation of European Risk ...
... US Farms, Inc. (Pink Sheets: USFM) today announced that it ... ( www.edisastersystems.com ) based out of City of ... , Yan Skwara, CEO for US Farms, Inc. ... and soothing burns and having our Aloe365(TM) Skin Gel registered ...
Cached Medicine News:Health News:Country's Most Decorated Gymnast New Spokesmom for BabyPlus 2Health News:2nd Knee Surgery Common Among Young Patients 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 2Health News:Early Defibrillator After Heart Attack May Not Pay Off 3Health News:Big Top Cupcake(TM) Brand Awarded With Guinness World Record For World's Largest Cupcake 2Health News:Crawford & Company's Broadspire Unit Continues Its European Expansion 2Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 2Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 3Health News:US Farms, Inc. Becomes a Registered Seller of Its Aloe365(TM) Skin Gel With Emergency Disaster Systems, Inc. 4
Skin Tone External Eyelid Weights...
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Zone Quick is a simple and accurate system that measures tear volume in just 15 seconds per eye. Each box has an easy to read diagnostic indicator rule....
... Stent has been introduced by FCI Ophthalmics, Inc. ... Lacrimal Stent addressed the limitations previously encountered with ... DCR. Brought in to position through the nose, ... is no need to pass the very large ...
Medicine Products: